Genclis SAS appoints Mr. Stephane Boissel as CEO NANCY,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genclis SAS appoints Mr. Stephane Boissel as CEO

NANCY, France, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Genclis, an innovative diagnostic company in the fields of allergy and cancer, announced today the appointment of Mr. Stéphane Boissel as CEO. His appointment as a Board Member will be proposed to the next Shareholder Meeting.

Dr. Bernard Bihain, MD, Founder and Chairman of the Board of Genclis, stated: "Genclis is today transitioning from an R&D company towards an integrated company with marketing, and sales with the goal of becoming rapidly profitable. The recruitment of Stéphane Boissel as CEO fits perfectly well in this context. He brings to us more than 20 years of successful international finance and business development credentials, all critical features for Genclis going forward".

Mr. Stéphane Boissel, CEO of Genclis, said: "Joining Genclis is a fantastic and exciting challenge. The team put together by Bernard Bihain pioneered the discovery of breakthroughs in the field of allergy and cancer diagnostics. This excellent science has now turned into concrete products. We will focus on achieving wide market acceptance of these products by rapidly confirming their clinical utility, while we also enrich our pipeline thanks to continuous innovative genomic R&D".

Prior to joining Genclis, Mr. Stéphane Boissel was EVP and CFO of Transgene (2010 to 2014). Prior to Transgene, Mr. Boissel worked at Innate Pharma, firstly as CFO and then as EVP and CFO (2002 to 2010). During his tenure at Transgene and Innate Pharma, he led several rounds of private and public placement totaling more than 150 million euros and negotiated several business deals in the US, EU and Asia. Mr. Boissel is or was a board member of several biotechnology companies, including Erytech Pharma and ElsaLys Biotech. He started his career at PWC (1990 to 1994). He then joined the investment banking group Lazard where he mostly worked in principal investment, in France, Singapore and Hong Kong (1994 to 2002). He under graduated in economics at the University of Lyon, graduated at Paris-Dauphine and then obtained his MBA from the Chicago Booth Graduate Business School. Stéphane is a French CFA (SFAF).

About Genclis:

Genclis is an innovative genomic diagnostic company in the fields of allergy and cancer. Started in 2004, the Company initiated the commercialization of its allergy molecular diagnostic tests in 2014.

Genclis sells its products in French-speaking Europe through a dedicated platform: Galileo©. Galileo also distribute other allergy products from partners. Outside of its distribution zone, the Company sells its products through a distribution agreement with US-based Hycor, a rapidly emerging player in the field of allergy diagnostic.

In the field of cancer diagnostic, Genclis based its development on the concept of DNA/RNA transcription infidelity, an original, proprietary disruptive science. This science has already led to encouraging results in the severity prognostic of triple-negative breast cancer ("TNBC"), a very heterogeneous group of cancers including some types known to be very aggressive with poor prognosis. Genclis intends to rapidly achieve acceptance of its solution, Severidia©, as a standard for oncologists to offer their patients alternative treatment and monitoring options.

Based in Nancy and Paris, Genclis had 40 employees as of October 1, 2014. Please visit: www.genclis.com and www.galileodiagnostics.com .

Contacts:

Stéphane Boissel , CEO: +33674780925 - sboissel@genclis.com

Bernard Bihain, Chairman and CSO: +33633029088 - bbihain@genclis.com

pr nomination Boissel Stéphane http://hugin.info/164309/R/1862614/653510.pdf

HUG#1862614

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 95

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 128

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 20

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 27

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing FPSO Market Set to Reach $174 Billion by 2031

Updated Category News Views 101

Insights into the Floating Production Storage Offloading Market The Floating Production Storage Offloading (FPSO) market is emerging as a cornerstone in the offshore oil and gas industry. As global oil demands continue to escalate, industries and stakeholders are directing their attention towards FPSO technologies, which combine production and storage capabilities to...

Continue Reading
3D Systems Corporation Faces Potential Securities Fraud Lawsuit

Updated Category News Views 207

Potential Securities Fraud Lawsuit Against 3D Systems Corporation Investors in 3D Systems Corporation have a significant opportunity as rumors of a securities fraud lawsuit surface. This potential lawsuit is connected to claims of misleading statements made by the company regarding its financial performance and market outlook. Overview of the Allegations According to...

Continue Reading
Latest Insights into the U.S. Real Estate Landscape Today

Updated Category News Views 368

Understanding Recent Trends in U.S. Real Estate In recent months, the real estate market in the United States has demonstrated some fascinating trends. Notably, many Americans are choosing to stay in their homes rather than moving. In fact, only 11% moved in a recent year, a stark contrast to historical figures where up to a third of the population changed residences...

Continue Reading
Venture Global, Inc. Investors Encouraged to Take Action Soon

Updated Category News Views 285

Important Deadlines for Venture Global, Inc. Investors Investors of Venture Global, Inc. should pay close attention to approaching deadlines related to an ongoing securities class action. Those who purchased stock pursuant to the company's initial public offering (IPO) that took place in early 2025 have significant rights that might not require any out-of-pocket expense....

Continue Reading
Vatn Systems Makes Strategic Acquisition to Boost AUV Tech

Updated Category News Views 160

Vatn Systems' Strategic Move to Enhance Underwater Technology In an exciting development for the defense technology sector, Vatn Systems has made a significant advancement by acquiring Crewless Marine. This decision is part of Vatn's strategy to improve its autonomous underwater vehicles (AUVs), highlighting the importance of acoustic capabilities in undersea warfare....

Continue Reading